Enterprise Value

863.3M

Cash

403.9M

Avg Qtr Burn

-49.58M

Short % of Float

24.30%

Insider Ownership

2.16%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

ZORYVE® (Roflumilast foam 0.3%) Details
Skin disease/disorder, Seborrheic dermatitis

Approved

Quarterly sales

ZORYVE® (ARQ-151) topical roflumilast cream (PDE4 Inhibitor) Details
Psoriasis, Skin disease/disorder, Chronic obstructive pulmonary disease, Pulmonary hypertension

Approved

Quarterly sales

PDUFA

Approval decision

sNDA

Submission

sNDA

Submission

ARQ-255 topical ivarmacitinib (JAK1 inhibitor) Details
Skin disease/disorder, Alopecia areata

Phase 1b

Data readout

ARQ-252 (JAK1i) Details
Skin disease/disorder, Eczema

Failed

Discontinued

Failed

Discontinued